首页> 外文期刊>Clinical proteomics. >An integrated quantification method to increase the precision, robustness, and resolution of protein measurement in human plasma samples
【24h】

An integrated quantification method to increase the precision, robustness, and resolution of protein measurement in human plasma samples

机译:一种综合量化方法,以提高人血浆样品中蛋白质测量的精度,鲁棒性和分辨率

获取原文
获取原文并翻译 | 示例
           

摘要

Background Current quantification methods for mass spectrometry (MS)-based proteomics either do not provide sufficient control of variability or are difficult to implement for routine clinical testing. Results We present here an integrated quantification (InteQuan) method that better controls pre-analytical and analytical variability than the popular quantification method using stable isotope-labeled standard peptides (SISQuan). We quantified 16 lung cancer biomarker candidates in human plasma samples in three assessment studies, using immunoaffinity depletion coupled with multiple reaction monitoring (MRM) MS. InteQuan outperformed SISQuan in precision in all three studies and tolerated a two-fold difference in sample loading. The three studies lasted over six months and encountered major changes in experimental settings. Nevertheless, plasma proteins in low ng/ml to low μg/ml concentrations were measured with a median technical coefficient of variation (CV) of 11.9% using InteQuan. The corresponding median CV using SISQuan was 15.3% after linear fitting. Furthermore, InteQuan surpassed SISQuan in measuring biological difference among clinical samples and in distinguishing benign versus cancer plasma samples. Conclusions We demonstrated that InteQuan is a simple yet robust quantification method for MS-based quantitative proteomics, especially for applications in biomarker research and in routine clinical testing.
机译:背景技术基于质谱(MS)的质谱法(MS)的蛋白质组学不提供足够的可变性控制,或者难以实现常规临床测试。结果我们在此提供了一种集成量化(Intrcaran)方法,可更好地使用稳定同位素标记的标准肽(Sisquan)的流行定量方法进行预分析和分析可变性。我们在三项评估研究中量化了16种肺癌生物标志物候选人类样品中的候选,使用免疫亲和性耗竭与多重反应监测(MRM)MS相结合。在所有三项研究中,IntreCan精确地表现出Sisquan,并且耐受样品载荷的两倍差异。这三项研究持续了六个月,遇到了实验环境的重大变化。然而,使用Intrcaran的11.9%的中值技术系数(CV)测量低Ng / ml至低μg/ ml浓度的等离子体蛋白。线性配件后使用Sisquan的相应中值CV为15.3%。此外,Intrecan超过了Sisquan测量临床样品的生物学差异,并在区分良性与癌等离子体样本中。结论我们证明了IntreChan是一种简单而坚固的定量方法,适用于基于MS的数量蛋白质组学,特别是对于生物标志物研究和常规临床测试中的应用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号